Navigation Links
Eastern Clinical Trials Russia CRO Passes EMA Inspection
Date:2/12/2013

Moscow, Russia (PRWEB) February 12, 2013

Moscow, Russia January 31, 2013 -- Eastern Clinical Trials (ECT), a leading contract research organization (CRO) with operations in Russia and Central and Eastern Europe, announced today that it successfully passed with no major findings an inspection conducted by the European Medicines Agency (EMA).

The Inspection was conducted on 22-24 January 2013 at the site of Professor Sergey V. Orlov MD, PhD, of Saint Petersburg State Medical University, who is a principal investigator in a large registration oncology trial.

“We are very pleased to have passed the EMA Inspection” commented Dr. Svetlana Vodolazhskaya, Managing Director of Eastern Clinical Trials. “The Agency’s inspection results confirm that ECT's clinical research operations meet and often exceed international standards. We realize the importance of efficient operations that meet our client’s high requirements in drug development process and take great pride in both the quality of our work and in ECT's exceptional team of professionals.”

About Eastern Clinical Trials (ECT)(http://www.easterntrials.com)
Established in 2004, Eastern Clinical Trials (ECT) has grown from a local Moscow-based CRO to a trusted regional partner in clinical research with operations in Russia, Ukraine, Belarus, Georgia, Hungary and Slovakia. ECT provides a full spectrum of clinical trial services including project management, monitoring, study feasibility, regulatory submission and support, translation, safety reporting and warehousing.

Contact:
Svetlana Vodolazhskaya, MD
Managing Director
Russia 119034 Moscow
Tel: + 7(925)5023189
svetlana.vodolazhskaya(at)easterntrials(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10421281.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
2. Reminder: Spherix to Hold Business Update Conference Call April 11 at 1:00 p.m. Eastern Time
3. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
4. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
5. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
6. Cutting the Cost of Clinical Research: The Solution Comes from Russia, New Xtalks Webinar
7. OpenClinica to Exhibit at SCOPE (Summit for Clinical Ops Executives)
8. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
9. Migraines Found Linked to Nighttime Teeth Grinding & Clenching in TMJ Treatment Clinical Trial - Holistic Technologies
10. MC Leeuwarden Selects ClinicalKey
11. ComplianceOnline Announces Seminar on Clinical Trial Project Supplier Quality Improvement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):